The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-20 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
As a passenger during a long car drive, when insulin needs are different due to inactivity. While driving on an extended trip, to reduce the risk of hypoglycemia, a lower temporary basal rate may be programmed. During and after spontaneous exercise or sports activities, when the body needs less insulin. During illness or stress, when basal demand increases due to insulin resistance. When blood ketones are present, when additional insulin is needed. When on an extended fast (such as Ramadan, Lent, or Yom Kippur) when basal requirements may be lower. During menses, when additional basal insulin might be needed.
Experiments done in dwarf chameleons testing these hypotheses showed that chameleon taxa with greater capacity for color change had more visually conspicuous social signals but did not come from more visually diverse habitats, suggesting that color change ability likely evolved to facilitate social signaling, while camouflage is a useful byproduct. Because camouflage is used for multiple adaptive purposes in cephalopods, color change could have evolved for one use and the other developed later, or it evolved to regulate trade offs within both.
Presence of AIDS with low pretreatment CD4 count, typically <100 cells/microL. An exception is in the setting of Mycobacterium tuberculosis infection, which can be reactivated with CD4 cells >200 cells/microL. Decrease in HIV-1 RNA levels from baseline or increase in CD4 count after starting ART No evidence of drug-resistant infection, bacterial superinfection, adverse drug reaction, patient non-adherence, or reduced serum drug levels (from drug-drug interactions or malabsorption). Clinical symptoms consistent with an inflammatory condition Temporal association between initiation of ART and symptom onset The differential diagnosis of IRIS is broad given its varied presentation. Conditions that can present similarly to IRIS are: adverse drug effects, progression of initial OI caused by medication resistance or patient non-adherence, and development of a new OI.
β-Melanocyte-stimulating hormone (β-MSH) is an endogenous peptide hormone and neuropeptide. It is a melanocortin, specifically, one of the three types of melanocyte-stimulating hormone (MSH), and is produced from proopiomelanocortin (POMC). It is an agonist of the MC1, MC3, MC4, and MC5 receptors. It contains 23 amino acid residues. β-MSH is also known to decrease food intake in animals such as rats, chicken due to the effect of proopiomelanocortin (POMC). Research was performed to see the effect β-MSH has on chicks, and it has been found that chicks responded with a decrease in food and water intake when treated with β-MSH. The experiment showed that β-MSH causes anorexigenic effects in chicks.
Sources: en.wikipedia.org
=== Roads and highways === As of May 2010, the borough had a total of 37.02 miles (59.58 km) of roadways, of which 33.65 miles (54.15 km) were maintained by the municipality and 3.37 miles (5.42 km) by Bergen County. County Route 505 and County Route 501 travel through Cresskill.
The ability to learn new vocalizations is only exemplified in humans, seals, cetaceans, elephants and possibly bats; in humans, this is the result of a direct connection between the motor cortex, which controls movement, and the motor neurons in the spinal cord.
=== Film and other TV appearances === In addition to the game shows for which he became famous, Barker also hosted the annual/biennial Pillsbury Bake-Off (the bake-off occurred every two years starting in 1976). In 1978, he was the first host to have a male category champ. From 1969-1988 he also co-hosted CBS's coverage of the Rose Parade from Pasadena, California. On September 7, 2009, Barker was a special guest host for WWE Raw (called "The Price is Raw") in Rosemont, Illinois. Aired during a period when nearly every episode of the weekly wrestling show featured a celebrity guest host, with mixed results, Barker's appearance has been ranked the best of nearly 80 hosts. Barker also agreed to be a rotating guest co-host on The Huckabee Show, a daily TV talk show hosted by Mike Huckabee. Barker first appeared on the show on July 29, 2010. Barker's fame from his television hosting roles also saw him become a popular guest on other shows, including as a semi-regular panelist on the game shows Tattletales (1975–1976, with wife Dorothy Jo) and Match Game (1973–1980). Barker sat in Richard Dawson's former place during the first week after Dawson permanently left Match Game. Barker also made appearances on various talk shows such as: Dinah!, Larry King Live, The Arsenio Hall Show, Crook & Chase, Donny & Marie, The Rosie O'Donnell Show, The Ellen DeGeneres Show, The Wayne Brady Show, the Late Show with David Letterman, and The Late Late Show with Craig Ferguson.
=== 2006–2013: Rise to prominence and subsequent hiatus === Larter auditioned for the science fiction drama television series Heroes on NBC while living in Los Angeles. She played the characters of Niki Sanders, who suffered from dissociative identity disorder, and Tracy Strauss on the show created by Tim Kring. Larter's initial character Niki Sanders, was a wife, mother, and a former internet stripper from Las Vegas exhibiting superhuman strength and alternate personalities who go by the names of Jessica and Niki. "Ali read for the part and just owned it from the second she walked in," Kring said to the Chicago Tribune, "It was a very impressive audition." In the third and fourth seasons, Larter played the new character of Tracy Strauss, who possessed the ability to freeze objects and later, transform her body into water. Larter took on the title role in Marigold (2007), alongside Salman Khan, an Indian actor. The film was released in August 2007 and revolved around Marigold Lexington, an American actress (Larter) who goes to India and gets caught up in the exotic world of Bollywood. Filming took place in North India and London, commencing in June 2004. In an interview with the BBC, Larter remarked this role was "an opportunity to overcome my fear of singing and dancing because I have no professional training... I really focused on the character and loved this journey she went on and the experiences she had." She was paid a seven-figure salary for her part in the film.
== Stereochemistry == Citalopram has one stereocenter, to which a 4-fluoro phenyl group and an N, N-dimethyl-3-aminopropyl group bind. As a result of this chirality, the molecule exists in (two) enantiomeric forms (mirror images). They are termed S-(+)-citalopram and R-(–)-citalopram.
Sources: en.wikipedia.org
== History == Vinblastine was first isolated by Robert Noble and Charles Thomas Beer at the University of Western Ontario from the Madagascar periwinkle plant. The structure of Vinblastine and Vincristine are very similar. There are some differences in their pharmacological effects only and there is no cross-resistance. Vinblastine's utility as a chemotherapeutic agent was first suggested by its effect on the body when an extract of the plant was injected in rabbits to study the plant's supposed anti-diabetic effect. (A tea made from the plant was a folk-remedy for diabetes.) The rabbits died from a bacterial infection, due to a decreased number of white blood cells, so it was hypothesized that vinblastine might be effective against cancers of the white blood cells such as lymphoma. It was approved by FDA in 1965.
2 December – Neville Callaghan, 77, racehorse trainer. 5 December – Rosemary Smith, 86, rally driver. 7 December – Thomas Kilroy, 89, playwright and novelist. 10 December Jonathan Irwin, 82, blood stock agent, auctioneer, stud owner, publisher and founder of the Jack and Jill Foundation. Syd Millar, 89, rugby union player (Ballymena, national team), coach (British & Irish Lions) and International Rugby Board chairman (2003–2007). Born in Northern Ireland. Bill McCarthy, 87, hurler (St Brendan's, Ardfert, Kerry junior team, Munster). 11 December – Frank Twomey, 68, children's television entertainer and comedian (Bosco, Bull Island). 16 December – Joseph Finnegan, 81, judge. 17 December – Maureen Flavin Sweeney, 100, postmistress and formerly a weather forecaster notable for advising on the D-Day landings. 20 December – Johnny Flaherty, 76, hurler (Kinnitty, Offaly senior team, Leinster). 21 December – Martin Feeley, 73, Olympic rower (1976) and surgeon. 27 December – Éamonn Draper, 83, actor and director. 28 December – Patrick Walsh, 92, Roman Catholic prelate, bishop of Down and Connor (1991–2008). 30 December – Paddy Murphy, 89, Gaelic footballer (Dromtarriffe, Duhallow, Cork senior team.
== In platelets == The granules of platelets are classified as dense granules and alpha granules. α-Granules are unique to platelets and are the most abundant of the platelet granules, numbering 50–80 per platelet 2. These granules measure 200–500 nm in diameter and account for about 10% of platelet volume. They contain mainly proteins, both membrane-associated receptors (for example, αIIbβ3 and P-selectin) and soluble cargo (for example, platelet factor 4 [PF4] and fibrinogen). Proteomic studies have identified more than 300 soluble proteins that are involved in a wide variety of functions, including hemostasis (for example, von Willebrand factor [VWF] and factor V), inflammation (for example, chemokines such as CXCL1 and interleukin-8), and wound healing (for example, vascular endothelial growth factor [VEGF] and fibroblast growth factor [FGF]) 3. The classic representation of α-granules as spherical organelles with a peripheral limiting membrane, a dense nucleoid, and progressively lucent peripheral zones on transmission electron microscopy is probably simplistic and may be in part a preparation artifact. Electron tomography with three-dimensional reconstruction of platelets is notable for a significant percentage of tubular α-granules that generally lack VWF 4. More recent work using transmission electron microscopy and freeze substitution dehydration of resting platelets shows that α-granules are ovoid with a generally homogeneous matrix and that tubes form from α-granules upon activation 5.
The bounty was also reduced to £3 for trained men and £2.10s 0d for recruits, which resulted in finding £1,175,000 of the total savings required from the army as a whole. An innovation in 1922 was the creation of two Air Defence Brigades to provide anti-aircraft defence for London. It appears that these two brigades relatively quickly became 26th and 27th Air Defence Brigades. During the 1930s, tensions increased between Germany and the United Kingdom and its allies. In late 1937 and throughout 1938, German demands for the annexation of Sudetenland in Czechoslovakia led to an international crisis. To avoid war, the British Prime Minister Neville Chamberlain met with German Chancellor Adolf Hitler in September and brokered the Munich Agreement. The agreement averted a war and allowed Germany to annex the Sudetenland. Although Chamberlain had intended the agreement to lead to a further peaceful resolution of issues, relations between both countries soon deteriorated. On 15 March 1939, Germany breached the terms of the agreement by invading and occupying the remnants of the Czech state. On 29 March, Secretary of State for War Leslie Hore-Belisha announced plans to increase the TA from 130,000 to 340,000 men and double the number of TA divisions.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.